STLN
Starling Oncology Inc.
STLN | NASDAQ
$6.53
-$0.12 (-1.80%)
At close: Oct 30, 2026, 3:59 PM ET
$6.62
+$0.09 (+1.38%)
Pre-market:
Nov 2, 2026, 7:09 AM ET
Fiscal Quarter Period Ending | Q2 2026 Jun 30, 2026 | Q1 2026 Mar 31, 2026 | Q4 2025 Dec 31, 2025 | Q3 2025 Sep 30, 2025 |
|---|---|---|---|---|
Net Income | -9.79M | -2.49M | -7.51M | -16.5M |
Depreciation & Amortization | 1.84M | 1.62M | 1.63M | 1.72M |
Stock-Based Compensation | 1.07M | 1.69M | 1.32M | 1.02M |
Other Working Capital | 4.78M | 3.86M | -2.72M | 528K |
Other Non-Cash Items | 4.52M | -3.95M | 139K | 7.3M |
Deferred Income Tax | n/a | n/a | n/a | n/a |
Change in Working Capital | 14.3M | 928K | 7.65M | -6.17M |
Operating Cash Flow | 11.94M | -2.22M | 3.23M | -12.63M |
Capital Expenditures | -908K | -1.04M | -1.06M | -604K |
Cash Acquisitions | n/a | n/a | n/a | n/a |
Purchase of Investments | n/a | n/a | n/a | n/a |
Sales Maturities Of Investments | n/a | n/a | n/a | n/a |
Other Investing Acitivies | n/a | n/a | n/a | n/a |
Investing Cash Flow | -908K | -1.04M | -1.06M | -604K |
Debt Repayment | -8K | -9K | -9K | -8K |
Common Stock Repurchased | n/a | n/a | n/a | n/a |
Dividend Paid | n/a | n/a | n/a | n/a |
Other Financial Acitivies | -300K | -260K | -350K | -235K |
Financial Cash Flow | -218K | -28K | 3.73M | 10.6M |
Net Cash Flow | 10.81M | -3.29M | 5.91M | -2.63M |
Free Cash Flow | 11.03M | -3.26M | 2.17M | -13.23M |
Adj. Free Cash Flow | 9.96M | -4.94M | 856K | -14.26M |
Maintenance CapEx | -908K | -1.04M | -1.06M | -604K |
Growth CapEx | n/a | n/a | n/a | n/a |
Owner Earnings | 11.03M | -3.26M | 2.17M | -13.23M |
Add to Watchlist
Select watchlists to add or remove STLN